Compare Stocks: DRUG, TRLV, URGN, and XERS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DRUG Bright Minds Biosciences	$52.65 +2.5%	$65.86	$47.23 ▼ $123.75	$511.22M	-5.22	206,875 shs	68,512 shs
TRLV Trulieve Cannabis	$10.20 +0.9%	$10.95	$4.62 ▼ $13.28	$1.97B	N/A	945,672 shs	294,142 shs
URGN Urogen Pharma	$38.82 +1.5%	$43.78	$16.36 ▼ $50.81	$1.90B	1.57	819,583 shs	98,697 shs
XERS Xeris Biopharma	$10.30 +1.0%	$8.74	$5.25 ▼ $11.33	$1.87B	0.53	2.00 million shs	291,897 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DRUG Bright Minds Biosciences	-4.91%	+6.45%	-18.71%	-32.35%	-20.95%
TRLV Trulieve Cannabis	-2.28%	-4.84%	-10.25%	+18.38%	+1,014,999,900.00%
URGN Urogen Pharma	-0.05%	-7.65%	-9.57%	-3.87%	+128.28%
XERS Xeris Biopharma	-2.49%	+1.29%	+36.91%	+17.24%	+28.30%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DRUG Bright Minds Biosciences	$52.65 +2.5%	$65.86	$47.23 ▼ $123.75	$511.22M	-5.22	206,875 shs	68,512 shs
TRLV Trulieve Cannabis	$10.20 +0.9%	$10.95	$4.62 ▼ $13.28	$1.97B	N/A	945,672 shs	294,142 shs
URGN Urogen Pharma	$38.82 +1.5%	$43.78	$16.36 ▼ $50.81	$1.90B	1.57	819,583 shs	98,697 shs
XERS Xeris Biopharma	$10.30 +1.0%	$8.74	$5.25 ▼ $11.33	$1.87B	0.53	2.00 million shs	291,897 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DRUG Bright Minds Biosciences	-4.91%	+6.45%	-18.71%	-32.35%	-20.95%
TRLV Trulieve Cannabis	-2.28%	-4.84%	-10.25%	+18.38%	+1,014,999,900.00%
URGN Urogen Pharma	-0.05%	-7.65%	-9.57%	-3.87%	+128.28%
XERS Xeris Biopharma	-2.49%	+1.29%	+36.91%	+17.24%	+28.30%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DRUG Bright Minds Biosciences	2.90	Moderate Buy	$143.83	173.21% Upside
TRLV Trulieve Cannabis	2.00	Hold	$15.00	47.12% Upside
URGN Urogen Pharma	2.70	Moderate Buy	$52.38	34.92% Upside
XERS Xeris Biopharma	2.43	Hold	$13.20	28.17% Upside

Current Analyst Ratings Breakdown

Latest DRUG, TRLV, URGN, and XERS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/6/2026	XERS Xeris Biopharma	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$12.00 ➝ $14.00
9/28/2026	DRUG Bright Minds Biosciences	Lifesci Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
9/15/2026	DRUG Bright Minds Biosciences	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Hold
9/11/2026	TRLV Trulieve Cannabis	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/10/2026	XERS Xeris Biopharma	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$12.00 ➝ $16.00
9/10/2026	URGN Urogen Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$56.00
8/20/2026	DRUG Bright Minds Biosciences	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Market Perform
8/20/2026	DRUG Bright Minds Biosciences	Benchmark Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/20/2026	XERS Xeris Biopharma	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$9.00 ➝ $12.00
8/19/2026	DRUG Bright Minds Biosciences	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$145.00
8/17/2026	DRUG Bright Minds Biosciences	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$147.00

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$8.33 per share	N/A
TRLV Trulieve Cannabis	$1.18B	1.66	N/A	N/A	N/A	∞
URGN Urogen Pharma	$109.79M	17.28	N/A	N/A	($2.25) per share	-17.25
XERS Xeris Biopharma	$291.85M	6.43	$0.10 per share	104.43	$0.08 per share	128.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DRUG Bright Minds Biosciences	-$8.74M	-$2.08	N/A	N/A	N/A	N/A	-12.46%	-12.30%	12/22/2026 (Estimated)
TRLV Trulieve Cannabis	-$116.38M	$0.11	92.78	17.89	N/A	-41.55%	-4.24%	-1.72%	N/A
URGN Urogen Pharma	-$153.49M	-$1.98	N/A	11.12	N/A	-51.73%	N/A	-43.79%	11/5/2026 (Estimated)
XERS Xeris Biopharma	$550K	-$0.11	N/A	34.33	N/A	-5.12%	338.21%	3.50%	11/5/2026 (Estimated)

Latest DRUG, TRLV, URGN, and XERS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	URGN Urogen Pharma	$0.1025	N/A	N/A	N/A	$90.58 million	N/A
11/5/2026	Q3 2026	XERS Xeris Biopharma	$0.0317	N/A	N/A	N/A	$101.68 million	N/A
8/14/2026	Q3 2026	DRUG Bright Minds Biosciences	-$1.2230	-$0.17	+$1.0530	-$0.17	N/A	N/A
8/7/2026	Q2 2026	TRLV Trulieve Cannabis	$0.06	$0.11	+$0.05	-$2.10	$268.82 million	$271.00 million
8/6/2026	Q2 2026	XERS Xeris Biopharma	$0.0121	-$0.18	-$0.1921	-$0.18	$90.13 million	$92.10 million
8/5/2026	Q2 2026	URGN Urogen Pharma	-$0.2650	-$0.28	-$0.0150	-$0.28	$63.55 million	$72.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
TRLV Trulieve Cannabis	N/A	N/A	N/A	N/A	N/A
URGN Urogen Pharma	N/A	N/A	N/A	N/A	N/A
XERS Xeris Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DRUG Bright Minds Biosciences	N/A	122.00	122.00
TRLV Trulieve Cannabis	0.45	5.94	3.98
URGN Urogen Pharma	N/A	3.80	3.41
XERS Xeris Biopharma	17.00	1.45	1.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DRUG Bright Minds Biosciences	40.52%
TRLV Trulieve Cannabis	N/A
URGN Urogen Pharma	91.29%
XERS Xeris Biopharma	42.75%

Insider Ownership

Company	Insider Ownership
DRUG Bright Minds Biosciences	42.66%
TRLV Trulieve Cannabis	3.79%
URGN Urogen Pharma	4.80%
XERS Xeris Biopharma	4.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DRUG Bright Minds Biosciences	25	9.73 million	5.58 million	Not Optionable
TRLV Trulieve Cannabis	5,000	192.57 million	185.27 million	N/A
URGN Urogen Pharma	291	48.88 million	46.54 million	Optionable
XERS Xeris Biopharma	435	182.32 million	174.39 million	Optionable

DRUG, TRLV, URGN, and XERS Headlines

Recent News About These Companies

Organon & Co. (NYSE:OGN) & Xeris Biopharma (NASDAQ:XERS) Head to Head Review

October 14 at 4:15 AM | americanbankingnews.com

1,060,000 Shares of Xeris Biopharma Holdings, Inc. $XERS Bought by Vilga Financial Planning LLC

October 9, 2026 | marketbeat.com

Barclays raised Xeris Biopharma stock target to USD 14.00

October 8, 2026 | ad-hoc-news.deA

Why Xeris Biopharma Holdings (XERS) Is Up 5.8% After Raising 2026 Revenue Guidance And Retiring Debt

October 8, 2026 | finance.yahoo.com

Xeris Biopharma (NASDAQ:XERS) Stock Price Up 9.2% - Should You Buy?

October 5, 2026 | americanbankingnews.com

Xeris Biopharma (NASDAQ:XERS) Shares Climb 9.2% - Still a Buy?

October 5, 2026 | marketbeat.com

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - October 2, 2026

October 5, 2026 | biospace.comB

Xeris Biopharma (NASDAQ:XERS) Insider Steven Pieper Sells 5,000 Shares of Company Stock

October 3, 2026 | americanbankingnews.com

Xeris Biopharma (NASDAQ:XERS) Insider Steven Pieper Sells 5,000 Shares of Stock

October 3, 2026 | insidertrades.com

Xeris Biopharma (NASDAQ:XERS) Insider Beth Hecht Sells 16,666 Shares of Stock

October 3, 2026 | americanbankingnews.com

Xeris Biopharma (NASDAQ:XERS) Stock: Insider Steven Pieper Sells 5,000 Shares

October 2, 2026 | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Insider Kevin Mcculloch Sells 15,000 Shares of Stock

October 2, 2026 | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Insider Sells 16,666 Shares of Stock

October 2, 2026 | marketbeat.com

Update: Market Chatter: Lundbeck Said to Explore Potential Xeris Biopharma Acquisition

September 30, 2026 | finance.yahoo.com

Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells $250,000.00 in Stock

September 30, 2026 | insidertrades.com

Lundbeck approaches Xeris Biopharma over potential takeover, Bloomberg reports

September 29, 2026 | finance.yahoo.com

Xeris Biopharma reportedly draws takeover interest — but firm says it’s not for sale

September 29, 2026 | msn.com

Xeris Biopharma (NASDAQ:XERS) Insider Sells 25,000 Shares of Stock

September 29, 2026 | marketbeat.com

Lundbeck expresses interest in buying Xeris, Bloomberg News reports

September 29, 2026 | marketscreener.comM

Xeris Biopharma jumps on report of interest from H Lundbeck

September 29, 2026 | msn.com

Xeris Biopharma (NASDAQ:XERS) Hits New 12-Month High - What's Next?

September 29, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DRUG, TRLV, URGN, and XERS Company Descriptions

Bright Minds Biosciences NASDAQ:DRUG

$52.66 +1.30 (+2.53%)

As of 10:58 AM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Trulieve Cannabis NYSE:TRLV

$10.16 +0.05 (+0.49%)

As of 10:58 AM Eastern

Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery. It produces approximately 550 stock keeping units, including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays. As of May 5, 2021, the company operated through 87 dispensaries in the United States. The company is headquartered in Quincy, Florida.

Urogen Pharma NASDAQ:URGN

$38.82 +0.56 (+1.46%)

As of 10:58 AM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Xeris Biopharma NASDAQ:XERS

$10.30 +0.11 (+1.03%)

As of 10:58 AM Eastern

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DRUG, TRLV, URGN, and XERS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DRUG, TRLV, URGN, and XERS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DRUG, TRLV, URGN, and XERS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DRUG, TRLV, URGN, and XERS Company Descriptions

Bright Minds Biosciences NASDAQ:DRUG

Trulieve Cannabis NYSE:TRLV

Urogen Pharma NASDAQ:URGN

Xeris Biopharma NASDAQ:XERS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DRUG, TRLV, URGN, and XERS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DRUG, TRLV, URGN, and XERS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DRUG, TRLV, URGN, and XERS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DRUG, TRLV, URGN, and XERS Company Descriptions

Bright Minds Biosciences NASDAQ:DRUG

Trulieve Cannabis NYSE:TRLV

Urogen Pharma NASDAQ:URGN

Xeris Biopharma NASDAQ:XERS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools